Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

LONDON BROKER RATINGS: Jefferies rates Future at 'hold'; Spirent upped

Wed, 15th Mar 2023 09:36

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

----------

FTSE 100

----------

Berenberg cuts AstraZeneca price target to 12,400 (12,600) pence - 'buy'

----------

JPMorgan raises Relx price target to 2,840 (2,810) pence - 'overweight'

----------

FTSE 250

----------

Berenberg raises Spirent Communications to 'buy' (hold) - price target 250 (300) pence

----------

Berenberg cuts Future price target to 1,780 (2,600) pence - 'buy'

----------

Jefferies starts Future with 'hold' - price target 1,300 pence

----------

JPMorgan reinitiates Petershill Partners with 'overweight' - price target 246 pence

----------

JPMorgan reinitiates Intermediate Capital with 'neutral' - price target 1,451 pence

----------

JPMorgan raises TP ICAP price target to 235 (210) pence - 'overweight'

----------

RBC cuts Close Brothers price target to 1,200 (1,250) pence - 'outperform'

----------

RBC cuts Direct Line price target to 180 (190) pence - 'sector perform'

----------

Deutsche Bank cuts Genuit price target to 378 (447) pence - 'buy'

----------

SMALL CAP

----------

Deutsche Bank cuts IQE rice target to 40 (60) pence - 'buy'

----------

Berenberg cuts Johnson Service price target to 155 (180) pence - 'buy'

----------

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Related Shares

More News
Today 08:40

TOP NEWS: AstraZeneca's Tagrisso plus chemo gets approval in China

(Alliance News) - AstraZeneca PLC on Wednesday celebrated the approval of Tagrisso plus chemotherapy for a cancer form in China, a day after a similar...

25 Jun 2024 09:05

TOP NEWS: AstraZeneca details mixed findings from cancer drug trials

(Alliance News) - AstraZeneca PLC on Tuesday announced a mixed bag of results for two of its leading cancer drugs Imfinzi and Tagrisso.

25 Jun 2024 07:48

LONDON BRIEFING: Mixed bag for Astra drug; Landsec ups Bluewater stake

(Alliance News) - London's FTSE 100 is set to tread water on Tuesday, with a slump for US tech shares overnight keeping a lid on enthusiasm.

25 Jun 2024 07:17

AstraZeneca posts mixed results from recent Imfinzi trials

(Sharecast News) - AstraZeneca announced contrasting results from two phase three trials involving its immunotherapy drug 'Imfinzi', or durvalumab, on...

24 Jun 2024 15:40

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave a boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies le...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.